Asciminib – March 2026

Tablet 20 mg, Tablet 40 mg

  • Brand names:
    • Scemblix®
  • Pharmaceutical Company:
    • NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED
  • Condition/Indication: Chronic myeloid leukaemia (CML)
  • Meeting Date: March 2026
Public Summary Documents
Last updated
11 March 2026